Xinwang Duan

Xinwang Duan


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2017 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
SJShangyi Jin
Shangyi Jin
MLMengtao Li
Mengtao Li
YFYongfei Fang
Yongfei Fang
QLQin Li
Qin Li
JLJu Liu
Ju Liu
XZXiao-Feng Zeng
Xiao-Feng Zeng
Rheumatoid arthritis patients are at higher risk of developing comorbidities. The main objective of this study was to evaluate the prevalence of major comorbidities in Chinese rheumatoid arthritis patients. We also aimed to identify factors associated with these comorbidities. Baseline demographic, clinical characteristics and comorbidity data from RA patients enrolled in the Chinese Registry of rhEumatoiD arthrITis (CREDIT) from Nov 2016 to August 2017 were presented and compared with those from five other registries across the world. Possible factors related to three major comorbidities (cardiovascular disease, fragility fracture and malignancy) were identified using multivariate logistic regression analyses. A total of 13,210 RA patients were included (80.6% female, mean age 52.9 years and median RA duration 4.0 years). Baseline prevalence rates of major comorbidities were calculated: CVD, 2.2% (95% CI 2.0–2.5%); fragility fracture, 1.7% (95% CI 1.5–1.9%); malignancy, 0.6% (95% CI 0.5–0.7%); overall major comorbidities, 4.2% (95% CI 3.9–4.6%). Advanced age was associated with all comorbidities. Male gender and disease duration were positively related to CVD. Female sex and longer disease duration were potential risk factors for fragility fractures. Ever use of methotrexate (MTX) was negatively related to baseline comorbidities. Patients with rheumatoid arthritis in China have similar prevalence of comorbidities with other Asian countries. Advanced age and long disease duration are possible risk factors for comorbidities. On the contrary, MTX may protect RA patients from several major comorbidities, supporting its central role in the management of rheumatoid arthritis.

28 March 2019 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
XQXiao-Juan Qiu
Xiao-Juan Qiu
XZXiu-Ling Zhang
Xiu-Ling Zhang
LCLai-Sheng Cai
Lai-Sheng Cai
CYChen Yan
Chen Yan
LYLe Yu
Le Yu
XDXinwang Duan
Xinwang Duan

26 December 2019 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
MQMingliang Qiu
Mingliang Qiu
LMLisha Mo
Lisha Mo
JLJuxiang Li
Juxiang Li
HLHua Liang
Hua Liang
WZWeina Zhu
Weina Zhu
WXWeidong Xu
Weidong Xu

23 September 2024 in RMD Open
Verified
Journal Article
Open access
PDF file
CHCan Huang
Can Huang
YLYutong Li
Yutong Li
ZWZiqian Wang
Ziqian Wang
SLShuDian Lin
ShuDian Lin
JZJiuliang Zhao
Jiuliang Zhao
MLMengtao Li
Mengtao Li
Objective Patients with systemic lupus erythematosus (SLE) have an increased risk of cardiovascular and cerebrovascular events (CCEs). Furthermore, CCE was a significant factor contributing to mortality in patients with SLE. However, no clinical model exists that can predict which patients are at high risk. The purpose of this study was to develop a practical model for predicting the risk of CCE in people with SLE. Methods This study was based on the Chinese SLE Treatment and Research Group cohort. A total of 2399 patients, who had a follow-up period of over 3 years and were diagnosed with SLE for less than 1 year at the start of the study, were included. Cox proportional hazards regression and least absolute shrinkage and selection operator regression were used to establish the model. Internal validation was performed, and the predictive power of the model was evaluated. Results During the follow-up period, 93 patients had CCEs. The prediction model included nine variables: male gender, smoking, hypertension, age of SLE onset >40, cutaneous involvement, arthritis, anti-β2GP1 antibody positivity, high-dose glucocorticoids and hydroxychloroquine usage. The model’s C index was 0.801. Patients with a prognostic index over 0.544 were classified into the high-risk group. Conclusion We have developed a predictive model that uses clinical indicators to assess the probability of CCE in patients diagnosed with SLE. This model has the ability to precisely predict the risk of CCE in patients with SLE. We recommended using this model in the routine assessment of patients with SLE.

16 January 2020 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
MQMingliang Qiu
Mingliang Qiu
LMLisha Mo
Lisha Mo
JLJuxiang Li
Juxiang Li
HLHua Liang
Hua Liang
WZWeina Zhu
Weina Zhu
WXWeidong Xu
Weidong Xu